A closely watched next-generation blood thinner being developed by Bristol Myers Squibb and Johnson & Johnson failed in one of three late-stage trials.
The drug, milvexian, is a selective factor XIa inhibitor designed to prevent harmful clotting in the blood. It’s being tested in three Phase 3 trials, in cases of acute coronary syndrome, and to address atrial fibrillation and prevent secondary strokes. BMS reported Friday that it’s shutting down the first trial, for acute coronary syndrome.
Acute coronary syndrome is an umbrella term for situations in which blood flow to the heart muscle suddenly drops due to factors like a clot or heart attack. BMS reported that an interim analysis showed milvexian is unlikely to meet the primary endpoint of the trial.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply